CompletedEarly Phase 1ACTRN12619000885190

Caffeine and anaerobic exercise performance: an exploration of caffeine’s effects on performance in young men and the influence of genotype on the variation in responses

The effect of CYP1A2 genotype on the ergogenic effects of caffeine during anaerobic exercise


Sponsor

Victoria University

Enrollment

18 participants

Start Date

Aug 1, 2019

Study Type

Interventional

Conditions

Summary

The aim of the study will be to investigate the effects of caffeine (3 mg/kg 60 min pre-exercise) on vertical jump performance, movement velocity in resistance exercise, muscular endurance, and power output. Additionally, the aim is to explore if the inter-individual variation in responses to caffeine ingestion influenced by variations in genotype. The study hypothesis is that individuals classified as AA genotype will experience greater improvements in exercise performance following caffeine ingestion than those with AC and CC genotypes.


Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 40 Yearss

Inclusion Criteria1

  • The sample size will consist of resistance-trained men. Resistance-trained men will be defined as having a minimum of 6 months of resistance training experience with a minimum weekly training frequency of two times on most weeks.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Caffeine supplementation. Dose: 3 mg per kg of body weight The duration of administration: only on one occasion. Mode of administration: oral tablet. Wash out period between the caffeine and place

Caffeine supplementation. Dose: 3 mg per kg of body weight The duration of administration: only on one occasion. Mode of administration: oral tablet. Wash out period between the caffeine and placebo conditions is from 4 to 7 days. The CYP1A2 genotype will be assessed using a buccal swab sample collected before the caffeine and placebo conditions.


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12619000885190


Related Trials